Angioimmunoblastic T-cell lymphoma is a rare blood cancer affecting white blood cells that typically appears in older adults, bringing with it a complex set of symptoms that can sometimes be mistaken for other conditions.
Understanding Angioimmunoblastic T-cell Lymphoma
Angioimmunoblastic T-cell lymphoma, commonly known as AITL, is a rare and fast-growing form of cancer that develops in the lymphatic system, the network of vessels and organs that helps the body fight infections. This disease specifically affects T lymphocytes or T cells, a type of white blood cell that normally destroys harmful organisms like viruses and bacteria. When these T cells become abnormal, they multiply uncontrollably and build up in the lymph nodes and other parts of the body, where they can no longer perform their protective function properly.[1][2]
The disease sits under the broader category of non-Hodgkin lymphoma and is classified as a type of peripheral T-cell lymphoma, or PTCL. Among the various subtypes of peripheral T-cell lymphomas, AITL is one of the more common forms, yet it remains rare overall. The cancer originates from specialized T cells called follicular T helper cells, which normally help B cells produce antibodies to fight infection.[4]
Epidemiology
While AITL represents one of the more common subtypes of T-cell lymphoma, it is still quite uncommon when compared to all forms of cancer. The disease accounts for approximately 20 to 30 percent of all peripheral T-cell lymphomas. In the United States, AITL makes up about 4 percent of all lymphoma cases and only 1 to 2 percent of all non-Hodgkin lymphoma cases. In broader terms, it comprises roughly 10 to 15 percent of all T-cell lymphomas and just 1 to 3 percent of all non-Hodgkin lymphomas.[1][2][5]
The disease shows a clear pattern in terms of age, most commonly affecting older individuals. The median age at diagnosis is around 65 years, though it can occasionally affect younger adults as well. The condition is most common in people over the age of 65, and typically affects elderly patients. Because AITL primarily appears in this older population, treatment decisions often need to account for other health conditions that may be present alongside the lymphoma.[1][2][5]
Causes
The exact cause of angioimmunoblastic T-cell lymphoma remains unclear to researchers. What is known is that AITL develops when T lymphocytes become abnormal and begin growing out of control. Instead of dying off naturally as cells normally would, these abnormal T cells continue to multiply and spread throughout the body. Scientists have not yet determined why some people develop this transformation of T cells while others do not.[2][3]
There may be connections between AITL and certain viral infections, particularly the Epstein-Barr virus, which is the virus that causes infectious mononucleosis. Some research has also identified possible links to other viruses including cytomegalovirus, HIV, and certain types of human herpesvirus. However, scientists still need more information to understand exactly why these connections exist and how they might contribute to the development of the disease.[2]
From a genetic perspective, AITL exhibits certain characteristic mutations in genes such as TET2, DNMT3A, RHOA, and IDH2. These mutations appear to occur in stages, with TET2 and DNMT3A mutations happening first in hematopoietic stem cells, which are the cells that give rise to all blood cells. Later, mutations in RHOA and IDH2 are detected specifically in the follicular T helper cells. Following these genetic changes, the affected T helper cells begin releasing various chemical signals called chemokines and cytokines that alter the surrounding tissue environment and promote the development of AITL.[4]
Risk Factors
A compromised immune system may increase the risk of developing various types of lymphoma, including AITL. Conditions that weaken the immune system, such as HIV infection, appear to contribute to a higher likelihood of developing these blood cancers. Additionally, certain genetic mutations may serve as risk factors for the disease. Mutations in genes including BCL-6, DNMT3A, TET2, IDH2, and others have been associated with an increased risk of developing angioimmunoblastic T-cell lymphoma.[2][17]
Advanced age represents another significant risk factor, as the disease predominantly affects individuals over 65 years old. While AITL can occur in younger adults, its incidence increases substantially with age. The disease shows regional differences in occurrence across different parts of the world, suggesting that environmental or genetic factors specific to certain populations may also play a role in disease risk.[4]
Symptoms
Because AITL is a fast-growing cancer, symptoms can develop quickly, sometimes appearing or worsening within just a few weeks. The rapid progression of the disease means that people often notice changes happening over a relatively short period. The most common symptom is painless swelling in areas where lymph nodes are located, particularly in the neck, armpit, or groin. These swollen lymph nodes can grow very quickly and typically do not cause discomfort or pain, even as they enlarge.[2][3]
Many people with AITL experience what doctors call B symptoms, a specific group of general symptoms that often indicate lymphoma. These include unexplained fever that comes and goes without an apparent cause, heavy sweating at night that may soak through clothing and bedsheets, and significant weight loss amounting to more than one-tenth of total body weight without trying to lose weight. Some individuals also develop unexplained itching of the skin. These systemic symptoms reflect the body’s response to the cancer and often indicate more advanced disease.[2][3]
AITL produces some unique symptoms that distinguish it from other types of lymphoma. Many patients develop a skin rash that may appear flat or raised, and can be itchy or scaly. The rash stems from the abnormal immune system activity triggered by the lymphoma cells. Shortness of breath may occur if fluid accumulates around the lungs, a condition called pleural effusions. Similarly, fluid can collect in the abdominal cavity, causing bloating and discomfort. Joint pain and swelling may develop due to inflammation caused by the body’s abnormal immune response to the lymphoma.[2][5][8]
When the lymphoma grows in the bone marrow, the cancer cells can crowd out normal blood cells, leading to low blood cell counts. This can cause persistent tiredness and shortness of breath from anemia, or increased bleeding and bruising from low platelet counts. An enlarged spleen or liver can cause a sensation of fullness or discomfort in the abdomen. Fatigue, or persistent tiredness, is common and can significantly affect daily activities and quality of life.[3][8]
Prevention
Currently, there are no known specific prevention strategies for angioimmunoblastic T-cell lymphoma. Because the exact causes of the disease are not fully understood, and because researchers have not identified clear preventable risk factors, there are no established lifestyle changes, vaccinations, or supplements that have been proven to prevent AITL. The genetic mutations associated with the disease appear to occur spontaneously, and the viral connections that have been identified do not yet provide clear pathways for prevention.[2]
The best approach for people concerned about AITL or lymphoma in general is to maintain overall good health through a balanced lifestyle, including regular medical checkups. While this may not prevent AITL specifically, staying attentive to unusual symptoms and seeking prompt medical evaluation when they occur can lead to earlier diagnosis. For individuals with compromised immune systems, managing the underlying condition with appropriate medical care may help reduce overall cancer risk, though this has not been specifically proven for AITL.[2]
Pathophysiology
The pathophysiology of AITL involves complex changes in how the body’s immune system functions. Under normal circumstances, T lymphocytes circulate through the blood and lymphatic system, working to identify and destroy harmful invaders like bacteria, viruses, and even cancer cells. In AITL, specific T cells called follicular T helper cells undergo genetic mutations that transform them into cancer cells. These abnormal cells then multiply uncontrollably, losing their normal protective functions.[2][3]
The abnormal T cells accumulate primarily in the lymph nodes, but they can also spread to other organs including the liver, lungs, spleen, and bone marrow. As they build up, these cells create a complex environment within the affected tissues. The tumor microenvironment in AITL contains not just the cancerous T cells, but also other types of cells including normal B cells, plasma cells, and specialized blood vessels. This mixed cellular environment is one of the characteristic features visible under a microscope when examining tissue from someone with AITL.[4][5]
A distinctive feature of AITL visible under microscopic examination is a convoluted network of small blood vessels surrounding the tumor cells. This gives the disease part of its name—”angio” referring to blood vessels. Additionally, large virus-infected cells called immunoblasts are often scattered throughout the affected tissue. These cells are believed to be part of the tumor process, contributing to the second part of the disease name—”immunoblastic.”[5]
The abnormal follicular T helper cells in AITL release large amounts of chemical messengers called cytokines and chemokines. These substances normally help coordinate immune responses, but in AITL they create excessive and inappropriate immune system activation. This overactive immune signaling leads to many of the unique symptoms seen in AITL, including the skin rashes, joint inflammation, autoimmune destruction of blood cells, and fluid accumulation in body cavities. The cytokines also stimulate B cells to multiply excessively and produce abnormal proteins, further disrupting normal immune function.[4][5]
The genetic mutations that drive AITL occur in a specific sequence. Early mutations in genes like TET2 and DNMT3A happen in hematopoietic stem cells, the precursor cells that give rise to all blood cells. These mutations alone don’t cause lymphoma but create cells that are more vulnerable to additional changes. Later, when additional mutations occur in genes like RHOA and IDH2 specifically in developing T helper cells, the combination of these genetic abnormalities drives the transformation into cancer. This multi-step process helps explain why AITL typically develops later in life, as it requires the accumulation of multiple genetic changes over time.[4]
When lymphoma cells invade the bone marrow, they physically take up space that would normally be occupied by developing blood cells. This crowding effect reduces the production of normal red blood cells, white blood cells, and platelets. The resulting low blood counts cause symptoms like fatigue from anemia, increased susceptibility to infections from low white blood cell counts, and easy bruising or bleeding from low platelet counts. This bone marrow involvement is common in AITL and contributes significantly to the disease burden experienced by patients.[3]
In some cases, AITL can lead to the development of an additional type of lymphoma called diffuse large B-cell lymphoma, an aggressive B-cell cancer. This transformation occurs when the abnormal immune environment created by AITL stimulates B cells to such an extent that they also become cancerous. This potential for transformation adds another layer of complexity to the disease and requires careful monitoring during diagnosis and treatment.[17]
